Valbenazine is a purified isomer of tetrabenazine drug, used to treat
tardive dyskinesia which is a nervous system disorder. Dyskinesia
refers to involuntary muscle movement that can range from slight
tremor to uncontrollable movement of the entire body. Grimacing,
tongue movements, lip smacking, lip puckering, pursing of the lips,
etc. are the common effects of tardive dyskinesia. Valbenazine drug
acts as a vesicular monoamine transporter 2 inhibitor, which is
essentially an integral membrane protein, and decreases the level of
dopamine in the body. Valbenazine decreases the level of monoamine
neurotransmitters by preventing their storage in synaptic vesicles.
The effect of this drug has been studied on pregnant women.
Subsequently, it is not recommended to pregnant or breastfeeding
women. The symptoms of tardive dyskinesia can be severe and are often
persistent and irreversible. Both valbenazine and its active
metabolite [+]-α-HTBZ have a half-life period of 15-22 hours and
Tmax of 0.5 to 1 hr.
Report Overview @
https://www.transparencymarketresearch.com/valbenazine-market.html
Based on class, the valbenazine market can be classified into
therapeutic (central nervous system agent), pharmacologic (monoamine
depletor), and chemical (benzoquinolizine). Demand for therapeutic
valbenazine is on the rise, as its effects on the central nervous
system help to cure the disease faster than the other drugs. In terms
of end-user, the valbenazine market can be segmented into hospitals,
clinical research centers, and academic research organizations. The
hospitals segment is expanding rapidly, as these settings are
preferred by patients for the treatment of tardive dyskinesia disease
or other brain cell disorders. Consumption of alcohol, mental stress,
and prolonged usage of neuroleptic drugs are the major factors
driving the valbenazine market. However, side effects associated with
anticonvulsants and stringent regulations on their usage are some of
the factors anticipated to hamper the growth of the market.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32486
North America leads the global valbenazine market because of
increasing use of antipsychotic drugs among adults and children in
the U.S. This has resulted in the rise in prevalence of tardive
dyskinesia. According to the American Academy of Neurology, the newly
diagnosed tardive dyskinesia disease incidence was 26,000, and the
incidence rate was 10.6 per 100,000 adults in the U.S. in 2016.
According to the WHO, neuropsychiatric disorder is the third leading
cause of disability-adjusted life years (DALYs) in Europe, and almost
15.2% of the people are affected by it. This creates a demand for
drugs such as valbenazine. Asia Pacific is expected to be the fastest
growing market for valbenazine drugs, due to increase in consumption
of alcohol, mental stress, and growth in population in countries such
as India and China. Prevalence of the disease varies according to
ethnic ancestry - people with Asian or African inheritance have a 1
in 1,000,000 risk of getting affected. Rise in awareness about mental
illness and improvement in the economy are estimated to drive the
market for valbenazine drug in Middle East & Africa.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=32486<ype=S
Neurocrine Biosciences Inc. is the only key player in the valbenazine
drug market.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment